Granted Patent
B2
US 12,473,559 · App. 18/467,952 · Granted Nov 18, 2025
Cas9/RNA complexes for inducing modifications of target endogenous nucleic acid sequences in nucleuses of eukaryotic cells
Assignee:
ToolGen Incorporated
C12N15/52C12N9/16C12N9/22C12N15/102C12N15/111C12N15/63C12N15/8216C12N15/85C12N15/907C12Y301/21C12N2310/10C12N2310/20C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to targeted genome editing in eukaryotic cells or organisms. More particularly, the present disclosure provides for Cas9/RNA complexes that may induce modifications in target endogenous nucleic acid sequences in nucleuses of eukaryotic cells. The Cas9/RNA complex may comprise a recombinant Cas9 protein including a nuclear localization signal (NLS) and a guide RNA including a crRNA and a tracrRNA. The Cas9/RNA complex may be a combination of the recombinant Cas9 protein and the guide RNA. The guide RNA may be transcribed in vitro or synthesized chemically. The target endogenous nucleic acid sequence may include a portion complementary to the crRNA of the guide RNA.
Claims (15)
1 . A method of inducing a modification of a target endogenous nucleic acid sequence in a nucleus of a human cell, comprising:
preparing a Cas9 protein, wherein the Cas9 protein comprises a nuclear localization signal (NLS);
preparing a single-guide RNA (sgRNA), wherein the sgRNA comprises a crRNA and a tracrRNA, wherein the sgRNA is transcribed in vitro or synthesized chemically, and wherein the target endogenous nucleic acid sequence includes a portion complementary to the crRNA of the sgRNA;
providing a buffer in an in vitro environment;
disposing the Cas9 protein into the buffer;
disposing the sgRNA into the buffer, wherein the sgRNA is disposed in at least a two-fold molar excess over the Cas9 protein in the buffer,
allowing the Cas9 protein and the sgRNA to complex in the in vitro environment to form a Cas9/sgRNA complex;
transfecting the Cas9/sgRNA complex into the human cell by electroporation, whereby the Cas9/sgRNA complex induces the modification of the target endogenous nucleic acid sequence in the nucleus of the human cell.
2 . The method of claim 1 , wherein electroporation is by nucleofection.
3 . The method of claim 1 , wherein the target endogenous nucleic acid comprises a trinucleotide protospacer adjacent motif (PAM) recognized by the Cas9 protein, wherein the PAM consists of trinucleotide 5′-NGG-3′.
4 . The method of claim 1 , wherein the NLS is at a C-terminus of the Cas9 protein.
5 . The method of claim 1 , wherein the crRNA is 20 nt in length.
6 . The method of claim 1 , wherein the modification includes one of a deletion, insertion, or substitution of at least one nucleotide.
7 . The method of claim 1 , wherein the method further comprises allowing the human cell to produce one or more progenies, wherein the modification of the target endogenous nucleic acid sequence is transmitted to at least some of the progenies of the human cell.
8 . The method of claim 7 , wherein the modification of the target endogenous nucleic acid sequence is transmitted to all of the progenies of the human cell.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 16, 2025
From: KIM, JIN-SOO; CHO, SEUNG WOO; KIM, SOJUNG
To: TOOLGEN INCORPORATED
Reel/Frame 072267/0631 →
Continuity (10)
Continuation
PCTKR2013009488
· Oct 23, 2013
Provisional Application
61837481
· Jun 20, 2013
Provisional Application
61803599
· Mar 20, 2013
Provisional Application
61717324
· Oct 23, 2012
Related Publication
20240240192A9
· Jul 18, 2024
References Cited (400)
US 5766900A
· Shillito et al.
· 1998
[cited by applicant]
US 5767367A
· Dudits et al.
· 1998
[cited by applicant]
US 5925517A
· Tyagi et al.
· 1999
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8771495B2
· Paneccasio, Jr. et al.
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8795965B2
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8871445B2
· Cong et al.
· 2014
[cited by applicant]
US 8883233B2
· Gillessen et al.
· 2014
[cited by applicant]
US 8889356B2
· Zhang et al.
· 2014
[cited by applicant]
US 8889418B2
· Zhang et al.
· 2014
[cited by applicant]
US 8889559B2
· Trapp et al.
· 2014
[cited by applicant]
US 8895308B1
· Zhang et al.
· 2014
[cited by applicant]
US 8906616B2
· Zhang et al.
· 2014
[cited by applicant]
US 8932814B2
· Cong et al.
· 2015
[cited by applicant]
US 8945839B2
· Zhang et al.
· 2015
[cited by applicant]
US 8993233B2
· Zhang et al.
· 2015
[cited by applicant]
US 8999641B2
· Zhang et al.
· 2015
[cited by applicant]
US 9023649B2
· Mali et al.
· 2015
[cited by applicant]
US 9260723B2
· Mali et al.
· 2016
[cited by applicant]
US 9493779B2
· Ainley et al.
· 2016
[cited by applicant]
US 9637739B2
· Šikšnys et al.
· 2017
[cited by applicant]
US 9840713B2
· Zhang
· 2017
[cited by applicant]
US 20050220796A1
· Dynan et al.
· 2005
[cited by applicant]
US 20100076057A1
· Sontheimer
· 2010
[cited by applicant]
US 20140179770A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186843A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186919A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140189896A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242664A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242699A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140273230A1
· Chen et al.
· 2014
[cited by applicant]
US 20140273233A1
· Chen et al.
· 2014
[cited by applicant]
US 20140310830A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140342456A1
· Mali et al.
· 2014
[cited by applicant]
US 20140349405A1
· Sontheimer et al.
· 2014
[cited by applicant]
US 20140357530A1
· Zhang et al.
· 2014
[cited by applicant]
US 20150020223A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150031134A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150050699A1
· Siksnys et al.
· 2015
[cited by applicant]
US 20150067922A1
· Yang et al.
· 2015
[cited by applicant]
US 20150184139A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150203872A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150225734A1
· Voytas et al.
· 2015
[cited by applicant]
US 20150232833A1
· Mali et al.
· 2015
[cited by applicant]
US 20150232882A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150240261A1
· Siksnys et al.
· 2015
[cited by applicant]
US 20150247150A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150259704A1
· Church et al.
· 2015
[cited by applicant]
US 20150291961A1
· Siksnys et al.
· 2015
[cited by applicant]
US 20150291965A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150344912A1
· Kim et al.
· 2015
[cited by applicant]
US 20160017366A1
· Chen et al.
· 2016
[cited by applicant]
US 20160046961A1
· Jinek et al.
· 2016
[cited by applicant]
US 20160060653A1
· Doudna et al.
· 2016
[cited by applicant]
US 20160060654A1
· Doudna et al.
· 2016
[cited by applicant]
US 20160068864A1
· Doudna et al.
· 2016
[cited by applicant]
US 20160115489A1
· Zhang et al.
· 2016
[cited by applicant]
US 20160153004A1
· Zhang et al.
· 2016
[cited by applicant]
US 20160168594A1
· Zhang et al.
· 2016
[cited by applicant]
US 20160281072A1
· Zhang
· 2016
[cited by applicant]
US 20170152528A1
· Zhang
· 2017
[cited by applicant]
US 20170198269A1
· Zhang et al.
· 2017
[cited by applicant]
US 20180230495A1
· Doudna et al.
· 2018
[cited by applicant]
US 20180230496A1
· Doudna et al.
· 2018
[cited by applicant]
US 20180230497A1
· Doudna et al.
· 2018
[cited by applicant]
US 20180251793A1
· Doudna et al.
· 2018
[cited by applicant]
US 20180251794A1
· Doudna et al.
· 2018
[cited by applicant]
US 20180251795A1
· Charpentier et al.
· 2018
[cited by applicant]
US 20190002921A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190002922A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190002923A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190010520A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190169645A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190169646A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190169647A1
· Doudna et al.
· 2019
[cited by applicant]
US 20190169648A1
· Doudna et al.
· 2019
[cited by applicant]
US 20210047648A1
· Kim et al.
· 2021
[cited by applicant]
AU 733057B2
· 2001
[cited by applicant]
AU 2011203213
· 2011
[cited by applicant]
CN 102358902A
· 2015
[cited by applicant]
CN 105658796A
· 2016
[cited by applicant]
EP 2825654
· 2014
[cited by applicant]
EP 3138910
· 2017
[cited by applicant]
EP 3138911
· 2017
[cited by applicant]
EP 2800811B1
· 2017
[cited by examiner]
EP 3360964
· 2018
[cited by applicant]
EP 3363902
· 2018
[cited by applicant]
JP S63102686A
· 1988
[cited by applicant]
JP H1080274A
· 1998
[cited by applicant]
JP H11502507A
· 1999
[cited by applicant]
JP 2001503971A
· 2001
[cited by applicant]
JP 2002538842A
· 2002
[cited by applicant]
JP 2005006578A
· 2005
[cited by applicant]
JP 2009505663
· 2009
[cited by applicant]
JP 2010539930A
· 2010
[cited by applicant]
JP 2012508002A
· 2012
[cited by applicant]
KR 1020150016588A
· 2015
[cited by applicant]
KR 1020150023670A
· 2015
[cited by applicant]
KR 1020150056539A
· 2023
[cited by applicant]
NZ 228948
· 1991
[cited by applicant]
WO WO1998010084A1
· 1998
[cited by applicant]
WO WO2000055378A1
· 2000
[cited by applicant]
WO WO02067996
· 2002
[cited by applicant]
WO WO2005054494
· 2005
[cited by applicant]
WO WO2005123962A2
· 2005
[cited by examiner]
WO WO2007024029
· 2007
[cited by applicant]
WO WO2007025195A1
· 2007
[cited by applicant]
WO WO2009042164
· 2009
[cited by applicant]
WO WO2010001189
· 2010
[cited by applicant]
WO WO2010052341A1
· 2010
[cited by applicant]
WO WO2010076939
· 2010
[cited by applicant]
WO WO2010076939A1
· 2010
[cited by applicant]
WO WO2011007193
· 2011
[cited by applicant]
WO WO2011056186A1
· 2011
[cited by applicant]
WO WO2011130346A1
· 2011
[cited by applicant]
WO WO2011146121
· 2011
[cited by applicant]
WO WO2011146121A1
· 2011
[cited by applicant]
WO WO2012012738A1
· 2012
[cited by applicant]
WO WO2012138939
· 2012
[cited by applicant]
WO WO2013098244A1
· 2013
[cited by applicant]
WO WO2013141680A1
· 2013
[cited by applicant]
WO WO2013142578A1
· 2013
[cited by applicant]
WO WO2013176772A1
· 2013
[cited by examiner]
WO WO2013176776A1
· 2013
[cited by applicant]
WO WO2013188522
· 2013
[cited by applicant]
WO WO2014018423A2
· 2014
[cited by applicant]
WO WO2014022702A2
· 2014
[cited by applicant]
WO WO2014065596A1
· 2014
[cited by applicant]
WO WO2014089290A1
· 2014
[cited by applicant]
WO WO2014093595A1
· 2014
[cited by applicant]
WO WO2014093622A2
· 2014
[cited by applicant]
WO WO2014093635A1
· 2014
[cited by applicant]
WO WO2014093655A2
· 2014
[cited by applicant]
WO WO2014093661A2
· 2014
[cited by examiner]
WO WO2014093694A1
· 2014
[cited by applicant]
WO WO2014093701A1
· 2014
[cited by applicant]
WO WO2014093709A1
· 2014
[cited by applicant]
WO WO2014093712A1
· 2014
[cited by examiner]
WO WO2014093718A1
· 2014
[cited by applicant]
WO WO2014099744A1
· 2014
[cited by applicant]
WO WO2014099750A2
· 2014
[cited by applicant]
WO WO2014144155A1
· 2014
[cited by applicant]
WO WO2014190181A1
· 2014
[cited by applicant]
WO WO2014197568A2
· 2014
[cited by applicant]
WO WO2014204725A1
· 2014
[cited by applicant]
WO WO2015026883A1
· 2015
[cited by applicant]
WO WO2008108989A2
· 2018
[cited by applicant]
WO WO02067966A1
· 2022
[cited by applicant]
Jinek et al “RNA-programmed genome editing in human cells” (eLife pp. 1-9; published online Jan. 29, 2013). (Year: 2013).
[cited by examiner]
Mali et al (Science vol. 339: pp. 823-826, Feb. 15, 2013, published online Jan. 2013). (Year: 2013).
[cited by examiner]
Wang et al (Cell vol. 153: pp. 1-9; May 9, 2013). (Year: 2013).
[cited by examiner]
Shen et al (Cell Research 2013 vol. 23: pp. 720-723, published online Apr. 2, 2013). (Year: 2013).
[cited by examiner]
Chang et al “Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos” Cell Research 2013 vol. 23: pp. 465-472, published online Mar. 26, 2013). (Year: 2013).
[cited by examiner]
Cho et al (“Targeted genome engineering in human cells with RNA-guided endonucleases” and corresponding Supplementary Information: Nature Biotechnology vol. 31, No. 3, Mar. 2013; published online Jan. 29, 2013) (Year: 2…
[cited by examiner]
Cho_et_al_Nature_Biotechnology_March_2013_Supplementary_Material (Year: 2013).
[cited by examiner]
Advisory Action mailed Aug. 21, 2017, in relation to U.S. Appl. No. 14/685,510 (3 pages).
[cited by applicant]
Advisory Action mailed Jun. 22, 2018, in relation to U.S. Appl. No. 14/685,510 (3 pages).
[cited by applicant]
Alberts et al., 1994, “Molecular Biology of the Cell, Third Edition,” Garland Publishing, Inc., New York & London, pp. 228 and 335 (4 pages).
[cited by applicant]
Amended Statement of Grounds and Particulars in Support of Opposition dated Jul. 13, 2017 in marked-up and clean copies, in relation to Australian Patent Application No. 2013335451 (19 pages).
[cited by applicant]
Andreas et al., 2002, “Enhanced efficiency through nuclear localization signal fusion on phage φC31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells”, Nucleic Acids Research, 30(11): 2299-…
[cited by applicant]
Anonymous, PCT Third Party Observation dated Feb. 19, 2015, in relation to International Application No. PCT/ KR2013/009488 filed on Oct. 23, 2013, pp. 1-5.
[cited by applicant]
Anonymous, Third Party Observation dated Sep. 18, 2015, in relation to European Patent Application No. EP13849670.8 (Publication No. EP 2 912 175 A1) filed Oct. 23, 2015 (74 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Jan. 9, 2017, in relation to European Patent Application No. EP13849670.8 (Publication No. EP 2912175 A1) filed Oct. 23, 2015 (74 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Feb. 16, 2015, in European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013 (12 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Feb. 3, 2015, in relation European Patent Application No. EP20130793997 (Publication No. EP2800811) filed Mar. 15, 2013 (3 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Feb. 5, 2015, in relation to European Patent Application No. EP20130793997 (Publication No. EP2800811) filed Mar. 15, 2013 (2 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Jul. 18, 2014, in relation to International Application No. PCT/US2013/033106 filed Mar. 20, 2013 (7 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Mar. 25, 2015, in relation to European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013 (7 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Nov. 7, 2014, in relation to European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013 (7 pages).
[cited by applicant]
Anonymous, Third Party Observation dated Sep. 24, 2014, in relation to International Application No. PCT/US2013/032589 filed Mar. 15, 2013 (8 pages).
[cited by applicant]
Anonymous, Third Party Observations dated Oct. 22, 2014, in relation to European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013, pp. 1-8.
[cited by applicant]
Anonymous, Third Party Observations dated Sep. 22, 2014, in relation European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013, pp. 1-19.
[cited by applicant]
Anonymous, Third Party Observations dated Sep. 8, 2014, in relation to European Patent Application No. EP20130824232 (Publication No. EP2764103) filed Dec. 12, 2013, pp. 1-48.
[cited by applicant]
Applicant-Initiated Interview Summary mailed Dec. 30, 2015, in relation to U.S. Appl. No. 14/685,510 (4 pages).
[cited by applicant]
Applicant-Initiated Interview Summary mailed Jul. 14, 2017, in relation to U.S. Appl. No. 14/685,510 (4 pages).
[cited by applicant]
Applicant-Initiated Interview Summary mailed May 11, 2016, in relation to U.S. Appl. No. 14/685,510 (3 pages).
[cited by applicant]
Applicant-Initiated Interview Summary mailed Nov. 17, 2016, in relation to U.S. Appl. No. 14/685,510 (3 pages).
[cited by applicant]
Applicant-Initiated Interview Summary mailed Sep. 22, 2017, in relation to U.S. Appl. No. 14/685,510 (4 pages).
[cited by applicant]
Friedland et al., 2013, “Heritable genome editing in C.elegans via a CRISPR-Cas 9 system”, Nat. Methods, 10(8): 1-12.
[cited by applicant]
Au et al., 2008, “Characterization of a baculovirus nuclear localization signal domain in the late expression factor 3 protein”, Virology, vol. 385: 209-217.
[cited by applicant]
Australian Patent Office General Correspondence dated Aug. 10, 2017 related to Opponent's Amended Statement of Grounds and Particulars in Support of Opposition dated Jul. 13, 2017 and Applicant's letter dated Jul. 31, 2…
[cited by applicant]
Baiker et al., 2004, “The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo”, J Virol., 78…
[cited by applicant]
Baker, 2014, “Gene editing at CRISPR speed”, Nat Biotechnol, 32(4): 309-312.
[cited by applicant]
Barrangou et al., 2007, “CRISPR provides acquired resistance against viruses in prokaryotes”, Science, 315(5819): 1709-1712.
[cited by applicant]
Barrangou, R., 2012, “RNA-mediated programmable DNA cleavage”, Nature Biotechnology, 30(9): 836-838.
[cited by applicant]
Bassett and Liu, 2014, “CRISPR/Cas9 and genome editing in
[cited by applicant]
Bassett et al., 2013, “Highly Efficient Targeted Mutagenesis of
[cited by applicant]
Bassett, A.R. and Liu, J.-L., 2014, “CRISPR/Cas9 and Genome Editing in
[cited by applicant]
Baum et al., 2010, “Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing”, PNAS, 107(37): 16303-16308.
[cited by applicant]
Bikard et al., 2012, “CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection”, Cell Host & Microbe, 12: 177-186.
[cited by applicant]
Bitter et al., 1987, “Expression and secretion vectors for yeast,” Methods Enzymol, 153: 516-544.
[cited by applicant]
Boch J. and Bonas U., 2010, “Xanthomonas AvrBs3 Family-Type III Effectors: Discovery and Function”, Annu. Rev. Phytopathol., 48: 419-436, first published online May 10, 2010.
[cited by applicant]
Bogerd et al., 2010, “A mammalian herpesvirus uses non-canonical expression and processing mechanisms to generate viral microRNAs”, Molecular Cell, 37: 135-142.
[cited by applicant]
Brothers et al., 2003, “Unexpected effects of epitope and chimeric tags on gonadotropin-releasing hormone receptors: implications for understanding the molecular etiology of hypogonadotropic hypogonadism”, J Clin Endocr…
[cited by applicant]
Brouns, S.J.J., “A Swiss Army Knife of Immunity”, Science, 2012, vol. 337: 808-809.
[cited by applicant]
Brummelkamp et al., 2002, “A system for stable expression of short interfering RNAs in mammalian cells”, Science, 296(5567): 550-553.
[cited by applicant]
Brzostek-Racine et al., 2011, “The DNA damage response induces IFN”, J Immunol, 187: 5336-5345.
[cited by applicant]
Burgess, D., 2013, “Technology: Characterizing CRISPR off-target effects”, Nat. Rev. Genet. 15, 5.
[cited by applicant]
Cain, C., 2013, “CRISPR genome editing”, SciBX Sci. Exch. 1-3, doi: 10.1038/scibx.2013.77.
[cited by applicant]
Carey et al., 2009, “Dignam and roeder nuclear extract preparation”, Cold Spring Harb Protoc, 4(12): 1-4.
[cited by applicant]
Carlson et al., 2012, “Cell-free protein synthesis: applications come of age”, Biotechnology Advances, 30: 1185-1194.
[cited by applicant]
Carrol, D., 2012, “A CRISPR Approach to Gene Targeting,” Molecular Therapy, 20(9): 1658-1660.
[cited by applicant]
Carroll, 2008, “Progress and prospects: zinc-finger nucleases as gene therapy agents,” Gene Ther., 15(22): 1463-1468.
[cited by applicant]
Carroll, 2011, “Genome engineering with zinc-finger nucleases”, Genetics, 188: 773-782.
[cited by applicant]
Carroll, 2012, “A CRISPR approach to gene targeting”, Molecular Therapy, 20(9): 1658-1660.
[cited by applicant]
Carroll, D., 2013, “Staying on target with CRISPR-Cas”. Nat. Biotechnol. 31: 807-809.
[cited by applicant]
Cermak et al., 2011, “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting”, Nucleic Acids Research, 2011, 39(12): e82, (11 pages) First published online Apr. 14, 2011.
[cited by applicant]
Cerritelli et al., 2009, “Ribonuclease H: the enzymes in eukaryotes,” FEBS J., 276(6): 1494-1505.
[cited by applicant]
Chalberg et al., 2005, “Integration specificity of phage phiC31 integrase in the human genome, ” J Mol Biol., 357(1): 28-48.
[cited by applicant]
Chan et al., 1988, “Characterization of the Kinetochore Binding Domain of CENP-E Reveals Interactions with the Kinetochore Proteins CENP-F and hBUBR1”, J. Cell Biol, 143(1): 49-63.
[cited by applicant]
Chang et al., 2013, “Genome editing with RNA-guided Cas9 nuclease in Zebrafish embryos”, Cell Research, 2013, 23(4): 465-472 and Supplementary Materials.
[cited by applicant]
Chen et al., 2007, “Transfection and expression of plasmid DNA in plant cells by an arginine-rich intracellular delivery peptide without protoplast preparation”, FEBS Letters, 581: 1891-1897.
[cited by applicant]
Chen, B. et al., 2013, “Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system”, Cell 155, 1479-1491.
[cited by applicant]
Chiu et al., 1996, “Engineered GFP as a viral reporter in plants”, Curr Biol, 6(3): 325-330.
[cited by applicant]
Christian et al. 2010, “Targeting DNA Double-Strand Breaks with TAL Effector Nucleases”, Genetics, 186: 757-761 and 2S1-8S1.
[cited by applicant]
Chuan et al., 2008, “High-level expression of soluble viral structural protein in
[cited by applicant]
Clark et al., 2011, “A TALE of two nucleases: gene targeting for the masses?” Zebrafish, 8(3): 147-149.
[cited by applicant]
Close et al., 2012, “Expression of non-native genes in a surrogate host organism”, Retrieved from the Internet at <http://www.intechopen.com> (33 pages).
[cited by applicant]
Cohen et al., 2011, “The emerging race to cure HIV infections”, Science, 332(6031): 784-789.
[cited by applicant]
Collins et al., 2010, “Cytosol as battleground: ubiquitin as a weapon for both host and pathogen”, Trends in Cell Biology, 20(4): 205-213.
[cited by applicant]
Coppoolse et al., 2003, “Cre recombinase expression can result in phenotypic abberations in plants”, Plant Molecular Biology, 51: 263-279.
[cited by applicant]
Cyranoski, 2016, “Updated: NgAgo gene-editing controversy escalates in peer-reviewed papers,” Nature, 540(7631): 20-21.
[cited by applicant]
David Bikard et al., 2013, “Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system”, Nucleic Acids Research, 41(15): 7429-7437.
[cited by applicant]
David J. Segal, 2013, “Genome engineering: Bacteria herald a new era of gene editing”, elife, vol. 2, e00563, pp. 1-3.
[cited by applicant]
Decision issued by Australian Patent Office, Opposition dated Sep. 18, 2018, in relation to Australian Patent Application No. 2013335451 (36 pages).
[cited by applicant]
Decision issued by PTAB on Motion Issued on Feb. 15, 2017 relating to Patent Interference No. 106,048 (DK).
[cited by applicant]
Decision issued by USPTO on Petition issued Jun. 17, 2013 in U.S. Appl. No. 13/842,859 (3 pages).
[cited by applicant]
Declaration of Dana Carroll in Support of Suggestion of Interference Pursuant to 37 C.F.R. § 41.202, executed Apr. 10, 2015, in relation to Patent Interference No. 106,048 (DK) (122 pages).
[cited by applicant]
Declaration of Dr. Marco Josef Herold, executed Jun. 15, 2017 in the matter of Opposition to the Australian Patent Application No. 2013335451.
[cited by applicant]
Declaration of Dr. Marco Josef Herold, executed Nov. 17, 2017 in the matter of Opposition to the Australian Patent Application No. 2013335451.
[cited by applicant]
Declaration of Dr. Ron Firestein, executed Sep. 19, 2017 in the matter of Opposition to the Australian Patent Application No. 2013335451.
[cited by applicant]
Declaration of Grant William Fisher, executed Jun. 15, 2017 in the matter of Opposition to the Australian Patent Application No. 2013335451.
[cited by applicant]
Declaration of Marco Joseph Herold dated Nov. 17, 2017, in relation to Australian Patent Application No. 2013335451 (7 pages).
[cited by applicant]
Declaration of Paul Quinton Thomas, executed Jun. 15, 2017 in the matter of Opposition to the Australian Patent Application No. 2013335451.
[cited by applicant]
Declaration of Technical Expert Paul Simons in Support of Broad et al., executed May 23, 2016, in relation to Patent Interference No. 106,048 (DK) (91 pages).
[cited by applicant]
Declaration of Technical Expert Paul Simons, executed Dec. 22, 2015, in relation to U.S. Appl. No. 14/704,551 (77 pages).
[cited by applicant]
Declaration of Technical Expert Ronald Breaker in Support of Broad et al., executed Aug. 15, 2016, in relation to Patent Interference No. 106,048 (DK) (34 pages).
[cited by applicant]
Deltcheva et al., 2011, “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III”, Nature, 471(7340): 602-607 and Supplementary Information (71 pages).
[cited by applicant]
Deng et al., 2012, “Structural basis for sequence-specific recognition of DNA by TAL effectors”, Science, 335(6069): 720-723.
[cited by applicant]
Deveau et al., 2008, “Phage Response to CRISPR-Encoded Resistance in
[cited by applicant]
DiCarlo et al., 2013, “Genome engineering in
[cited by applicant]
Dickinson et al., 2013, “Engineering the Caenorhabditis elegans genome using Cas9-triggered homologous recombination”, Nat. Methods, vol. 10: 1028-1034.
[cited by applicant]
Dingwall et al., 1982, “A polypeptide domain that specifies migration of nucleoplasm into the nucleus”, Cell, 30(2): 449-458, abstract only.
[cited by applicant]
Doudna, J., 2014, “The Crispr Revolution,” Catalyst Magazine, College of Chemistry, University of California, Berkeley, Jul. 9, 2014, pp. 1-4.
[cited by applicant]
Dr. A. Maschio, Response to EPO Communication dated Dec. 31, 2014, European Application No. 13824232.6, pp. 1-7.
[cited by applicant]
Dr. A. Maschio, Response to EPO Communication dated Jan. 5, 2015, European Application No. 13824232.6, pp. 1-2.
[cited by applicant]
Durai et al., 2005, “Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells”, Nucleic Acids Res., 33(18): 5978-5990.
[cited by applicant]
Edgar and Qimron, 2010, “The
[cited by applicant]
Edge.org, Mar. 2016, retrieved from the internet at <https://www.edge.org/conversation/george_church-the-augmented-human-being> (13 pages).
[cited by applicant]
Elbashir et al., 2001, “Duplexes of 21±nucleotide RNAs mediate RNA interference in cultured mammalian cells”, Nature, 411: 494-498.
[cited by applicant]
Ellis, 2001, “Macromolecular crowding: obvious but underappreciated”, Trends in Biochem Sci, 26(10): 597-604.
[cited by applicant]
Esvelt, K. M. et al., 2013, “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing”, Nat. Methods, vol. 10: 1116-1121.
[cited by applicant]
Notice of Opposition filed by CRISPR Therapeutics AG on Sep. 14, 2018, in relation to European Patent Application No. 13849670.8 (Patent No. EP 2912175 B1) (6 pages).
[cited by applicant]
Notice of Opposition filed by George W. Schlich on Aug. 22, 2018, in relation to European Patent Application No. 13849670.8 (Patent No. EP 2912175 B1) (8 pages).
[cited by applicant]
Notice of Opposition filed by Martin Grund on Aug. 30, 2018, in relation to European Patent Application No. 13849670.8 (Patent No. EP 2912175 B1) (7 pages).
[cited by applicant]
Anonymous, Third Party Observation filed Aug. 17, 2015, European Patent Application No. 13849670.8 (Publication No. EP 2912175 A1) (17 pages).
[cited by applicant]
Anonymous, Third Party Observation filed May 11, 2018, European Patent Application No. 13849670.8 (Publication No. EP 2912175 A1) (3 pages).
[cited by applicant]
Examiner's Answer to Appeal Brief mailed Nov. 9, 2018, in relation to U.S. Appl. No. 14/685,510 (29 pages).
[cited by applicant]
Extended European Search Report dated Nov. 9, 2015 for European Patent Application No. 13849670.8, 10 pages.
[cited by applicant]
Feng et al., 2013, “Efficient genome editing in plants using a CRISPR/Cas system,” Cell Res., 23(10): 1229-1232.
[cited by applicant]
Fieck et al., 1992, “Modifications of the
[cited by applicant]
First Declaration of Carol Greider, Ph.D, executed on May 23, 2016 in Support of University of California et al., Patent Interference No. 106,048 (DK) 1-873.
[cited by applicant]
First Declaration of Dana Carroll, Ph.D, executed on May 23, 2016 in Support of University of California et al., Patent Interference No. 106,048 (DK) 1-875.
[cited by applicant]
Fraley et al., 1983, “Expression of bacterial genes in plant cells”, Proc Natl Acad Sci USA, 80: 4803-4807.
[cited by applicant]
Frisher-Fantuzzi & Vesco, 1988, “Cell-Dependent Efficiency of Reiterated Nuclear Signals in a Mutant Simian Virus 40 Oncoprotein Targeted to the Nucleus”, Mol. Cell Biol, 8(12); 5495-5503.
[cited by applicant]
Fu et al., 2013, “High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells”, Nat Biotech, 31(9): 822-826.
[cited by applicant]
Fujii et al., 2013, “Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease”, Nucleic Acids Res., 41(20): e187.
[cited by applicant]
Fuqiang Chen et al., 2012, “Methods and Reagents for Modifying Genomes Using RNA-Guided Endonucleases”, in relation to U.S. Appl. No. 61/734,256.
[cited by applicant]
Gabriel et al., 2012, “An unbiased genome-wide analysis of zinc-finger nuclease specificity”, Nat Biotechnol, 29(9): 816-823.
[cited by applicant]
Gao et al., 2016, “DNA-guided genome editing using the Natronobacterium gregoryi Argonaute,” Nat Biotechnol., 34(7): 768-773 and Online Methods, Epub version.
[cited by applicant]
Garneau et al., 2010, “The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA”, Nature, Nov. 4, 2010, vol. 468: 67-71.
[cited by applicant]
Giedrius Gasiunas et al., 2012, “Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria”, PNAS, 109(39): 2579-2586.
[cited by applicant]
Gilbert, L. A. et al., 2013, “CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes”, Cell 154(2): 442-451.
[cited by applicant]
Goldberg, 2003, “Protein degradation and protection against misfolded or damaged proteins”, Nature, 426: 895-899.
[cited by applicant]
Goldfarb et al., 1986, “Synthetic peptides as nuclear localization signals”, Nature, 322: 641-644.
[cited by applicant]
Gonzalez et al, 2010, “Modular system for the construction of zinc-finger libraries and proteins”, Nature Protocols, 5(4): 791-810.
[cited by applicant]
Goren et al., 2012, “The bacterial CRISPR/Cas system as analog of the mammalian adaptive immune system”, RNA Biol, 9(5): 549-554.
[cited by applicant]
Görlich and Kutay, 1999, “Transport between the cell nucleus and the cytoplasm”, Annu Rev Cell Dev Biol, 15: 607-660.
[cited by applicant]
Gottwein et al., 2011, “Viral microRNA targetome of KSHV-infected primary effusion lymphoma cell lines”, Cell Host & Microbe, 10: 515-526.
[cited by applicant]
Greensan et al., 1988, “Two Nuclear Location Signals in the Influenza Virus NS1 Nonstructural Protein”, J. Virol, 52(8): 3020-3026.
[cited by applicant]
Gustafsson et al., 2004, “Codon bias and heterologous protein expression”, Trends in Biotechnology, 22(7): 346-353.
[cited by applicant]
Haoyi Wang et al., 2013, “One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering”, Cell., 153(4): 1-17.
[cited by applicant]
Hatfull, 2008, “Bacteriophage genomics”, Curr Opin Microbiol, 11(5): 447-453.
[cited by applicant]
Heidmann and Lehner, 2001, “Reduction of Cre recombinase toxicity in proliferating
[cited by applicant]
Hocine et al., 2010, “RNA processing and export”, Cold Spring Harbor Perspectives in Biology, retrieved from the internet at <http://cshperspectives.cship.org/> on Jun. 13, 2016 (21 pages).
[cited by applicant]
Houseley et al., 2009, The many pathways of RNA degradation, Cell, 136: 763-776.
[cited by applicant]
Hsu et al., 2013, “DNA targeting specificity of RNA-guided Cas9 nucleases”, Nature Biotechnology, doi: 10.1038/nbt.2647 (8 pages).
[cited by applicant]
Hwang et al., 2013, “Efficient in Vivo Genome Editing Using RNA-Guided Nucleases”, Nat Biotechnol., 31(3) Supplementary material, 18 pages.
[cited by applicant]
Imagawa et al., 2000, “Two nuclear localization signals are required for nuclear translocation of nuclear factor 1-A”, FEBS Letters, vol. 484: 118-124.
[cited by applicant]
James E. Dicarlo et al., 2013, “Genome engineering in
[cited by applicant]
Japanese Office Action dated Nov. 24, 2015 for Japanese Patent Application No. 2015-538033, pp. 1-10 (with English Translation).
[cited by applicant]
Jennifer A. Doudna et al., 2013, “Methods and Compositions for RNA-Directed Target DNA Modification and for RNA- Directed Modulation of Transcription”, U.S. Appl. No. 13/842,859, filed Mar. 15, 2013.
[cited by applicant]
Jenuwein et al., 1993, “The immunoglobulin u enhancer core establishes local factor access in nuclear chromatin independent of transcriptional stimulation”, Genes & Development, 7: 2016-2032.
[cited by applicant]
Jiang et al, 2011, “Structural basis of RNA recognition and activation by innate immune receptor RIG-I”, Nature, 479: 423-429.
[cited by applicant]
Jiang et al., 2013, “Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in
[cited by applicant]
Jiang, W. et al., 2013, “RNA-guided editing of bacterial genomes using CRISPR-Cas systems”, Nat. Biotechnol., vol. 31: 233-239.
[cited by applicant]
Jinek et al., 2012, “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity”, Science, 337(6096): 816-821 and Supplementary Materials (37 pages).
[cited by applicant]
PCT International Search Report dated Jan. 27, 2014, in relation to International Application No. PCT/KR2013/009488 filed Oct. 23, 2013, pp. 1-5.
[cited by applicant]
Karpala et al., 2005, “Immune responses to dsRNA: implications for gene silencing technologies”, Immun Cell Biol, 83: 211-216.
[cited by applicant]
Kennedy et al., 2014, “Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells using a bacterial CRISPR/Cas RNA-guided endonuclease”, Journal of Virology, 88: 11965-11972.
[cited by applicant]
Kim et al., 2009, “Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly”, Genome Research, 19: 1279-1288.
[cited by applicant]
Kim et al., 2011, “Surrogate reporters for enrichment of cells with nuclease-induced mutations”, Nat Methods, 8: 941-943.
[cited by applicant]
Kim et al., 2012, “Precision genome engineering with programmable DNA-nicking enzymes”, Genome Res, 22: 1327-1333.
[cited by applicant]
Kim et al., 2015, “Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier,” Sci Rep., 5:11719 (15 pages).
[cited by applicant]
Komar, 2008, “A pause for thought along the co-translational folding pathway”, Trends in Biochemical Sciences, 34(1): 16-24.
[cited by applicant]
Kondo et al., 2013, “Highly Improved Gene Targeting by Germline-Specific Cas9 Expression in
[cited by applicant]
Koonin, 2009, “Evolution of genome architecture”, Int J Biochem Cell Biol, 41(2): 298-306.
[cited by applicant]
Koseki et al., 1999, “Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III”, J Virol, 73(3): 1868-1877.
[cited by applicant]
Kosugi et al., 2009, “Six classes of nuclear localization signals specific to different binding grooves of importin α”, The Journal of Biological Chemistry, 284(1): 478-485.
[cited by applicant]
Krzysztof Chylinski et al., 2013, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems”, RNA Biology, 10(5): 727-737.
[cited by applicant]
Kuzuya et al., 2004, “Selective activation of two sites in RNA by acridine-bearing oligonucleotides for clipping of designated RNA fragments,” J Am Chem Soc., 126(5): 1430-1436.
[cited by applicant]
Lambowitz et al., 2011, “Group II Introns: Mobile Ribozymes that invade DNA,” Cold Spring Har. Perspecl. Biol., 3: a003616, pp. 1-19.
[cited by applicant]
Lander et al., 2001, “Initial sequencing and analysis of the human genome”, Nature, 409(6822): 860-921.
[cited by applicant]
Larson et al., 2011, “Real-time observation of transcription initiation and elongation on an endogenous yeast gene”, Science, 332(6028): 475-478.
[cited by applicant]
Larson, M. H. et al., 2013, “CRISPR interference (CRISPRi) for sequence-specific control of gene expression”, Nat. Protoc., 8: 2180-2196.
[cited by applicant]
Le Cong et al., 2013, “Multiplex Genome Engineering Using CRISPR/Cas Systems”, Science, 339(6121): 1-9 and Supplementary Materials (28 pages).
[cited by applicant]
Lechardeur et al., 1999, “Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer”, Gene Therapy, 6: 482-497.
[cited by applicant]
Lee et al., 2003, “Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector,” J Virol., 77(22): 11964-…
[cited by applicant]
Lee et al., 2010, “Targeted chromosomal deletions in human cells using zinc finger nucleases”, Genome Res, 20: 81-89.
[cited by applicant]
Lee et al., 2012, “Targeted chromosomal duplications and inversions in the human genome using zinc finger nucleases”, Genome Res, 22: 539-548.
[cited by applicant]
Lei S. Qi et al., 2013, “Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression”, Cell., 152(5): 1-22.
[cited by applicant]
Letter of Notice of Opposition dated Nov. 10, 2015 for European Patent No. EP2771468 (application No. EP 13818570.7) granted on Feb. 11, 2015, 57 pages.
[cited by applicant]
Letter of Notice of Opposition dated Jan. 8, 2016 for European Patent No. EP2784162 (application No. EP 14170383.5) granted on Apr. 8, 2015 (54 pages).
[cited by applicant]
Li et al., 2013, “Heritable gene targeting in the mouse and rat using a CRISPR-Cas system”, Nature Biotechnology, 31(8): 681-683 and Supplementary Information.
[cited by applicant]
Li et al., 2013, “Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems”, Nature Biotechnology, 31(8): 684-686 and Supplementary Information.
[cited by applicant]
Li et al., 2011, “Modularly Assembled Designer TAL Effector Nucleases for Targeted Gene Knockout and Gene Replacement in Eukaryotes,” Nucleic Acids Research, 39(14): 6315-6325.
[cited by applicant]
Li et al., 2013, “Multiplex and homologous recombination-mediated genome editing in
[cited by applicant]
Link and Breaker, 2009, “Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches”, Gene Therapy, 16: 1189-1201.
[cited by applicant]
Link et al., 2009, “Engineering ligand-responsive gene-control elements: lessons learned from natural riboswitches”, Gene Therapy, 16: 1189-1201.
[cited by applicant]
Liu et al., 2008, “Sequence space coverage, entropy of genomes and the potential to detect non-human DNA samples”, BMC Genomics, 9(509): 1-17.
[cited by applicant]
Lodish et al., 1995, Molecular Cell Biology, 3rd Ed., pp. 842-844.
[cited by applicant]
Loonstra et al., 2001, “Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells”, PNAS, 98(16): 9209-9214.
[cited by applicant]
Los et al., 2006, “Halotag Technology: Cell Imaging and Protein Analysis”, Cell Notes, vol. 14: 10-14.
[cited by applicant]
Luo et al., 2004, “Multiple Nuclear Localization Sequences Allow Modulation of 5-Lipoxygenase Nuclear Import”, Traffic, vol. 5: 847-854.
[cited by applicant]
Maasho et al., 2004, “Efficient gene transfer into the human natural killer cell line, NKL, using the Amaxa nucleofection system”, J Immunol Methods, 284(1-2): 133-140.
[cited by applicant]
Maeder, M. L. et al., 2013, “CRISPR RNA-guided activation of endogenous human genes”, Nat. Methods, vol. 10: 977-979.
[cited by applicant]
Mahfouz et al., 2011, “De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks”, Proc Natl Acad Sci USA, 108(6): 2623-2628.
[cited by applicant]
Mali et al., 2013, “CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering”, Nature Biotechnology, doi: 10.1038/ntb.2675 (8 pages).
[cited by applicant]
Mali et al., 2013, “Cas9 as a Versatile Tool for Engineering Biology”, Nature Methods, 10(10): 957-963.
[cited by applicant]
Mali et al., 2013, “RNA-Guided Human Genome Engineering via Cas9”, Science, 339(612): Supplementary material, 36 pages.
[cited by applicant]
Maraia et al., 2001, “La protein and the trafficking of nascent RNA polymerase III transcripts”, J Cell Biology, 153(4): F13-F17.
[cited by applicant]
Maraia et al., 2002, “La protein and its associated small nuclear and nucleolar precursor RNAs”, Gene Expression, 10: 41-57.
[cited by applicant]
Maresca, M. et al., 2013, “Obligate ligation-gated recombination (ObliGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous end joining”, Genome Res., 23: 539-546.
[cited by applicant]
Martin Jinek et al., “Methods and Compositions for RNA-Directed Site-Specific DNA Modification”, U.S. Appl. No. 61/652,086, filed May 25, 2012.
[cited by applicant]
Martin Jinek et al., 2013, “RNA-programmed genome editing in human cells”, elife, 2:e00471, pp. 1-9.
[cited by applicant]
Mastroianni et al., 2008, “Group II intron-based gene targeting reactions in eukaryotes”, PLoS One, 3(9): e3121 (15 pages).
[cited by applicant]
Mazzara et al., 2011, “Maturation events leading to transfer RNA and ribosomal RNA”, Cell Biology, 3: 439-545.
[cited by applicant]
McCall and Bender, 1996, “Probes for chromatin accessibility in the
[cited by applicant]
McShan et al., 2008, “Genome sequence of a nephritogenic and highly transformable M49 strain of
[cited by applicant]
Mefferd et al., 2015, “Expression of CRISPR/Cas single guide RNAs using small tRNA promoters,” RNA, 21(9): 1683-1689.
[cited by applicant]
Melissa Pandika, 2014, “Jennifer Doudna, CRISPR Code Killer”, www.ozy.com/rising-stars-and-provocateurs/jennifer-doudna-crispr-code-killer/4690, Jan. 7, 2014, pp. 1-6.
[cited by applicant]
Miao et al., 2013, “Targeted mutagenesis in rice using CRISPR-Cas system”, Cell Res., 23(10): 1233-1236.
[cited by applicant]
Miller et al., 2011, “A TALE nuclease architecture for efficient genome editing”, Nature Biotechnology,, 29 (2): 143-148 and online methods (2 pages).
[cited by applicant]
Minton, 2006, “How can biochemical reactions within cells differ from those in test tubes?”, Journal of Cell Science, vol. 119: 2863-2869.
[cited by applicant]
Mojica et al., 2009, “Short motif sequences determine the targets of the prokaryotic CRISPR defense system”, Microbiology, 155: 733-740.
[cited by applicant]
Morin et al., 1989, “Nuclear Localization of the Adenovirus DNA-Binding Protein: Requirement for Two Signals and Complementation during Viral Infection”, Mol. Cell Biol, 9(10): 4372-4380.
[cited by applicant]
Mussolino et al., 2011, “A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity”, Nucl Acids Res, 39(21): 9283-9293.
[cited by applicant]
Mussolino, C. & Cathomen, T., 2013, “RNA guides genome engineering”, Nat. Biotechnol. 31, 208-209.
[cited by applicant]
Nagarajan et al., 2004, “A Hierarchy of Nuclear Localization Signals X Complex Subunits and MHC Class II Governs the Import of the Regulatory Factor Expression”, J. Immunol, 173(1): 410-419.
[cited by applicant]
Nakai et al., 1999, “PSORT: a program for detecting sorting signals in proteins and predicting their subcellular localization,” Trends Biochem Sci., 24(1): 34-35.
[cited by applicant]
Nakamura et al., 2000, “Codon usage tabulated from international DNA sequence databases: status for the year 2000”, Nucleic Acids Research, 28(1): 292.
[cited by applicant]
Notice of Allowance and Fees Due dated Feb. 4, 2015, U.S. Appl. No. 14/226,274, filed Mar. 26, 2014, pp. 1-22.
[cited by applicant]
Nekrasov et al., 2013, “Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease,” Nat Biotechnol., 31(8): 691-693 and Supplemental Material.
[cited by applicant]
Notice of Allowance mailed Feb. 20, 2014 in connection with U.S. Appl. No. 14/054,414 (12 pages).
[cited by applicant]
Notice of Cross-Appeal filed by Respondents, Grant Fisher et al. on Nov. 6, 2018, in relation to Australian Patent Application No. 2013335451 (9 pages).
[cited by applicant]
O'Neill et al., 1992, “Nucleosome arrays inhibit both initiation and elongation of transcripts by bacteriophage T7 RNA polymerase”, J Mol Biol, 223:67-78.
[cited by applicant]
Office Action dated Sep. 1, 2015 for Australian Patent Application No. 2013335451 (3 pages).
[cited by applicant]
Ogawa, 2011, “Rational design of artificial riboswitches based on ligand-dependent modulation of internal ribosome entry in wheat germ extract and their applications as label-free biosensors”, RNA, 17: 478-488.
[cited by applicant]
Opponent's Summary of Submission dated May 7, 2018, in relation to Australian Patent Application No. 2013335451 (58 pages).
[cited by applicant]
Pablo Perez-Pinera et al., 2013, “RNA-guided gene activation by CRISPR-Cas9-based transcription factors”, Nat Methods, 10(10): 1-11.
[cited by applicant]
Paddison et al., 2002, “Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells”, Genes Dev., 16(8): 948-958.
[cited by applicant]
Paddison et al., 2005, “Cloning of short hairpin RNAs for gene knockdown in mammalian cells”, Nature Methods, 1(2): 163-167.
[cited by applicant]